Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 07:46 am
Share
Xenetic Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 0.349269 million compared to USD 0.115934 million a year ago. Net loss was USD 1.35 million compared to USD 7.56 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 1.2 a year ago.
For the nine months, revenue was USD 0.828088 million compared to USD 0.28561 million a year ago. Net loss was USD 3.8 million compared to USD 9.69 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 1.55 a year ago.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
XENETIC BIOSCIENCES, INC. 
